Beyond Body Weight: Biological and Clinical Determinants of Factor VIII Pharmacokinetics in Tunisian Patients
Haemophilia · 2026-11 · 32 (6) · 1413-1420
DOI: 10.1111/hae.70335 ↗Abstract
ABSTRACT Introduction Inter‐individual variability in factor VIII (FVIII) pharmacokinetics (PK) is well recognized in people with haemophilia A (PWH‐A) and may compromise the effectiveness of prophylaxis. This variability is partially explained by clinical and biological determinants, including age, anthropometric parameters and von Willebrand factor antigen (VWF:Ag) levels. Aim To identify the determinants of FVIII‐PK in Tunisian PWH‐A and assess their implications for PK‐guided prophylaxis. Methods A prospective PK study was conducted in 25 people with severe or moderate haemophilia A enrolled between December 2022 and December 2024. Following a 72‐hour wash‐out, PWH‐A received standard half‐life FVIII concentrates. FVIII activity was measured using one‐stage assay (OSA) and chromogenic substrate assay (CSA) at baseline, 30 min, 5 h ±1 h, 24 h and 48 h post‐infusion. PK parameters—half‐life, clearance, in vivo recovery and area under curve (AUC)‐ were calculated and correlated with age, anthropometric parameters, ABO blood group and VWF:Ag levels. Results FVIII activity measured by OSA and CSA showed a strong correlation ( p < 0.0001). Higher VWF:Ag levels were associated with longer FVIII half‐life ( p = 0.021) and lower clearance ( p = 0.027). Body mass index (BMI) correlated positively with IVR ( p = 0.007) while younger age was associated with higher clearance ( p = 0.037). No significant differences in PK parameters were observed between plasma‐derived and recombinant FVIII concentrates, except for higher AUC with plasma‐derived concentrates. Conclusion FVIII PK in Tunisian PWH‐A shows substantial inter‐individual variability. VWF:Ag levels, age and BMI were associated with PK parameters, supporting the implementation of individualized PK‐guided prophylaxis in Tunisia.
EUVIMED